Review ArticleREVIEWS AND CONTEMPORARY UPDATES
Open Access

Botulinum Toxin A: A Review of Potential Uses in Treatment of Female Urogenital and Pelvic Floor Disorders

Laurephile Desrosiers and Leise R. Knoepp
Ochsner Journal December 2020, 20 (4) 400-409; DOI: https://doi.org/10.31486/toj.19.0076

REFERENCES

  1. 1.↵
    1. Jankovic J,
    2. Hallet M
    1. DasGupta BR
    . Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, , Hallet M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker;1994:15.
  2. 2.↵
    1. Schantz EJ,
    2. Johnson EA
    . Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997 Spring;40(3):317-327. doi: 10.1353/pbm.1997.0032.
    OpenUrlCrossRef
  3. 3.↵
    1. Dykstra DD,
    2. Sidi AA
    . Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71(1):24-26.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    1. Sahai A,
    2. Dowson C,
    3. Khan MS,
    4. Dasgupta P
    ; GKT Botulinum Study Group. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010 Mar;75(3):552-558. doi: 10.1016/j.urology.2009.05.097.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Burke GS
    . Notes on Bacillus botulinus. J Bacteriol. 1919 Sep;4(5):555-570.1. doi: 10.1128/JB.4.5.555-570.1.1919.
    OpenUrlFREE Full Text
  6. 6.
    1. Aoki KR,
    2. Guyer B
    . Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001 Nov;8 Suppl 5:21-29. doi: 10.1046/j.1468-1331.2001.00035.x.
    OpenUrlCrossRef
  7. 7.↵
    1. Brin MF,
    2. Jankovic J,
    3. Hallett M
    1. Dolly JO,
    2. Lisk G,
    3. Foran PG,
    4. et al.
    Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Brin MF, , Jankovic J, , Hallett M, eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:91.
  8. 8.↵
    1. Giordano CN,
    2. Matarasso SL,
    3. Ozog DM
    . Injectable and topical neurotoxins in dermatology: basic science, anatomy, and therapeutic agents. J Am Acad Dermatol. 2017 Jun;76(6):1013-1024. doi: 10.1016/j.jaad.2016.11.022.
    OpenUrlCrossRef
  9. 9.
    1. Meunier FA,
    2. Schiavo G,
    3. Molgó J
    . Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002 Jan-Mar;96(1-2):105-113. doi: 10.1016/s0928-4257(01)00086-9.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Dressler D,
    2. Beneck R
    . Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehab. 2007 Dec 15;29(23):1761-1768. doi: 10.1080/09638280701568296.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Drugs@FDA: FDA-approved drugs. U.S. Food and Drug Administration. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed October 6, 2020.
  12. 12.↵
    Highlights of prescribing information. Botox (onabotulinumtoxinA). U.S. Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103000s5317lbl.pdf. Accessed October 6, 2020.
  13. 13.↵
    Botox (onabotulinumtoxinA). Drugs@FDA: FDA-approved drugs. U.S. Food and Drug Administration. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000. Accessed October 6, 2020.
  14. 14.↵
    1. Shepherd JP,
    2. Carter-Brooks CM,
    3. Chermanksy C
    . A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder. Int Urogynecol J. 2018 Aug;29(8):1213-1219. doi: 10.1007/s00192-018-3653-z.
    OpenUrlCrossRef
  15. 15.↵
    1. Brubaker L,
    2. Richter HE,
    3. Visco A,
    4. et al.
    Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217-222. doi: 10.1016/j.juro.2008.03.028.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.
    1. Flynn MK,
    2. Amundsen CL,
    3. Perevich M,
    4. Liu F,
    5. Webster GD
    . Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009 Jun;181(6):2608-2615. doi: 10.1016/j.juro.2009.01.117.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Sahai A,
    2. Khan MS,
    3. Dasgupta P
    . Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007 Jun;177(6):2231-2236. doi: 10.1016/j.juro.2007.01.130.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Duthie JB,
    2. Vincent M,
    3. Herbison GP,
    4. Wilson DI,
    5. Wilson D
    . Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3.
    OpenUrlCrossRef
  19. 19.↵
    1. Owen RK,
    2. Abrams KR,
    3. Mayne C,
    4. Slack M,
    5. Tincello DG
    . Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study). Neurourol Urodyn. 2017 Apr;36(4):1201-1207. doi: 10.1002/nau.23095.
    OpenUrlCrossRef
  20. 20.↵
    1. Chohan N,
    2. Hilton P,
    3. Brown K,
    4. Dixon L
    . Efficacy and duration of response to botulinum neurotoxin A (onabotulinumA) as a treatment for detrusor overactivity in women. Int Urogynecol J. 2015 Nov;26(11):1605-1612. doi: 10.1007/s00192-015-2751-4.
    OpenUrlCrossRef
  21. 21.↵
    1. Hsiao SM,
    2. Lin HH,
    3. Kuo HC
    . Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome. PLoS One. 2016 Jan 29;11(1):e0147137. doi: 10.1371/journal.pone.0147137.
    OpenUrlCrossRef
  22. 22.
    1. Drake MJ,
    2. Nitti VW,
    3. Ginsberg DA,
    4. et al.
    Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017 Nov;120(5):611-622. doi: 10.1111/bju.13945.
    OpenUrlCrossRef
  23. 23.↵
    1. Komesu YM,
    2. Amundsen CL,
    3. Richter HE
    , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018 Jan;218(1):111.e1-111.e9. doi: 10.1016/j.ajog.2017.10.006.
    OpenUrlCrossRef
  24. 24.↵
    1. Weckx F,
    2. Tutolo M,
    3. De Ridder D,
    4. Van der Aa F
    . The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol. 2016 Feb;5(1):63-71.
    OpenUrl
  25. 25.↵
    1. Cheng T,
    2. Shuang WB,
    3. Jia DD
    . Efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials. PloS One. 2016 Jul 27;11(7):e0159307. doi: 10.1371/journal.pone.0159307.
    OpenUrlCrossRef
  26. 26.↵
    1. Cruz F,
    2. Herschorn S,
    3. Aliotta P,
    4. et al.
    Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011 Oct;60(4):742-750. doi: 10.1016/j.eururo.2011.07.002.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Karsenty G,
    2. Elzayat E,
    3. Delapparent T,
    4. St-Denis B,
    5. Lemieux MC,
    6. Corcos J
    . Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol. 2007 Mar;177(3):1011-1014. doi: 10.1016/j.juro.2006.10.047.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Emami M,
    2. Shadpour P,
    3. Kashi AH,
    4. Choopani M,
    5. Zeighami M
    . Abobotulinum – a toxin injection in patients with refractory idiopathic detrusor overactivity: injections in detrusor, trigone and bladder neck or prostatic urethra, versus detrusor-only injections. Int Braz J Urol. 2017 Nov-Dec;43(6):1122-1128.
    OpenUrl
  29. 29.↵
    1. Apostolidis A,
    2. Dasgupta P,
    3. Denys P
    , et al; European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009 Jan;55(1):100-119. doi: 10.1016/j.eururo.2008.09.009.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Jarvis SK,
    2. Abbott JA,
    3. Lenart MB,
    4. Steensma A,
    5. Vancaillie TG
    . Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):46-50. doi: 10.1111/j.1479-828X.2004.00163.x.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Abbott JA,
    2. Jarvis SK,
    3. Lyons SD,
    4. Thomson A,
    5. Vancaille TG
    . Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):915-923. doi: 10.1097/01.AOG.0000237100.29870.cc.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Adelowo A,
    2. Hacker MR,
    3. Shapiro A,
    4. Modest AM,
    5. Elkadry E
    . Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013 Sep-Oct;19(5):288-292. doi: 10.1097/SPV.0b013e3182989fd8.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Nesbitt-Hawes EM,
    2. Won H,
    3. Jarvis SK,
    4. Lyons SD,
    5. Vancaillie TG,
    6. Abbott JA
    . Improvement in pelvic pain with botulinum toxin type A–single vs. repeat injections. Toxicon. 2013 Mar 1;63:83-87. doi: 10.1016/j.toxicon.2012.11.018.
    OpenUrlCrossRef
  34. 34.↵
    1. Morrissey D,
    2. El-Khawand D,
    3. Ginzburg N,
    4. Wehbe S,
    5. O'Hare P,
    6. Whitmore K
    . Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: a 6-month prospective pilot study. Female Pelvic Med Reconstr Surg. 2015 Sep-Oct;21(5):277-282. doi: 10.1097/SPV.0000000000000177.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Murina F,
    2. Karram M,
    3. Salvatore S,
    4. Felice R
    . Fractional CO2 laser treatment of the vestibule for patients with vestibulodynia and genitourinary syndrome of menopause: a pilot study. J Sex Med. 2016 Dec;13(12):1915-1917. doi: 10.1016/j.jsxm.2016.10.006.
    OpenUrlCrossRef
  36. 36.↵
    1. Wu C,
    2. Goldstein A,
    3. Klebanoff JS,
    4. Moawad GN
    . Surgical management of neuroproliferative-associated vestibulodynia: a tutorial on vestibulectomy with vaginal advancement flap. Am J Obstet Gynecol. 2019 Nov;221(5):525.e1-525.e2. doi: 10.1016/j.ajog.2019.08.009.
    OpenUrlCrossRef
  37. 37.↵
    1. Brin MF,
    2. Vapnek JM
    . Treatment of vaginismus with botulinum toxin injections. Lancet. 1997 Jan 25;349(9047):252-253. doi: 10.1016/S0140-6736(05)64862-3.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Shafik A,
    2. El-Sibai O
    . Vaginismus: results of treatment with botulin toxin. J Obstet Gynaecol. 2000 May;20(3):300-302. doi: 10.1080/01443610050009674.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Gunter J,
    2. Brewer A,
    3. Tawfik O
    . Botulinum toxin A for vulvodynia: a case report. J Pain. 2004 May;5(4):238-240. doi: 10.1016/j.jpain.2004.02.575.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Dykstra DD,
    2. Presthus J
    . Botuliniun toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med. 2006 Jun;51(6):467-470.
    OpenUrlPubMed
  41. 41.
    1. Yoon H,
    2. Chung WS,
    3. Shim BS
    . Botulinum toxin A for the management of vulvodynia. Int J Impot Res. 2007 Jan-Feb;19(1):84-87. doi: 10.1038/sj.ijir.3901487.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.
    1. Pelletier F,
    2. Parratte B,
    3. Penz S,
    4. Moreno JP,
    5. Aubin F,
    6. Humbert P
    . Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol. 2011 Mar;164(3):617-622. doi: 10.1111/j.1365-2133.2011.10235.x.
    OpenUrlCrossRefPubMed
  43. 43.
    1. Tieu KD,
    2. MacGregor JL
    . Successful treatment of vulvodynia with botulinum toxin A. Arch Dermatol. 2011 Feb;147(2):251-252. doi: 10.1001/archdermatol.2010.443.
    OpenUrlCrossRefPubMed
  44. 44.
    1. Jarrell J,
    2. Esfahani MN,
    3. Arendt-Nielsen L
    . Expansion of cutaneous allodynia in women with chronic pelvic pain due to visceral disease. Paper presented at: Pain in Europe, Congress of the European Federation of IASP Chapters (EFIC); October 9-12, 2013; Florence, Italy.
  45. 45.↵
    1. Park AJ,
    2. Paraiso MFR
    . Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia. Obstet Gynecol. 2009 Aug;114(2 Pt 2):484-487. doi: 10.1097/AOG.0b013e3181998ce1.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Petersen CD,
    2. Giraldi A,
    3. Lundvall L,
    4. Kristensen E
    . Botulinium toxin type A–a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled double blinded study. J Sex Med. 2009 Sep;6(9):2523-2537. doi: 10.1111/j.1743-6109.2009.01378.x.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Halder GE,
    2. Scott L,
    3. Wyman A,
    4. et al.
    Botox combined with myofascial release physical therapy as a treatment for myofascial pelvic pain. Investig Clin Urol. 2017 Mar;58(2):134-139. doi: 10.4111/icu.2017.58.2.134.
    OpenUrlCrossRef
  48. 48.↵
    1. Nesbitt‐Hawes EM,
    2. Dietz HP,
    3. Abbott JA
    . Four‐dimensional ultrasound guidance for pelvic floor botulinum toxin‐A injection in chronic pelvic pain: a novel technique. Ultrasound Obstet Gynecol. 2018 Mar;51(3):396-400. doi: 10.1002/uog.17537.
    OpenUrlCrossRef
  49. 49.↵
    1. Kuo YC,
    2. Kuo HC
    . Adverse events of intravesical onabotulinumtoxina injection between patients with overactive bladder and interstitial cystitis—different mechanisms of action of Botox on bladder dysfunction? Toxins (Basel). 2016 Mar 16;8(3):75. doi: 10.3390/toxins8030075.
    OpenUrlCrossRef
  50. 50.↵
    1. Chuang YC,
    2. Kuo HC
    . A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis/bladder pain syndrome. J Urol. 2017 Aug;198(2):376-382. doi: 10.1016/j.juro.2017.02.021.
    OpenUrlCrossRef
  51. 51.↵
    1. Pinto RA,
    2. Costa D,
    3. Morgado A,
    4. et al.
    Intratrigonal onabotulinumtoxinA improves bladder symptoms and quality of like in bladder pain syndrome/interstitial cystitis patients: a pilot, single center, randomized, double-blinded, placebo-controlled trial. J Urol. 2018 Apr;199(4):998-1003. doi: 10.1016/j.juro.2017.10.018.
    OpenUrlCrossRef
  52. 52.↵
    1. Rappaport YH,
    2. Zisman A,
    3. Jeshurun-Gutshat M,
    4. et al.
    Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in interstitial cystis/bladder pain syndrome patients: a pilot study. Urology. 2018 Apr;114:60-65. doi: 10.1016/j.urology.2017.12.028.
    OpenUrlCrossRef
  53. 53.↵
    1. Jiang YH,
    2. Jhang JF,
    3. Lee CL,
    4. Kuo HC
    . Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-a prospective, randomized, clinical trial. Neurourol Urdoyn. 2018 Apr;37(4):1467-1473. doi: 10.1002/nau.23475.
    OpenUrlCrossRef
  54. 54.↵
    1. Gallien P,
    2. Reymann JM,
    3. Amarenco G,
    4. Nicolas B,
    5. de Sèze M,
    6. Bellissant E
    . Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1670-1676. doi: 10.1136/jnnp.2004.045765.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Davies J,
    2. Duffy D,
    3. Boyt N,
    4. Aghahoseini A,
    5. Alexander D,
    6. Leveson S
    . Botulinum toxin (Botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study. Dis Colon Rectum. 2003 Aug;46(8):1097-1102. doi: 10.1007/s10350-004-7286-6.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Patti R,
    2. Almasio PL,
    3. Muggeo VM,
    4. et al.
    Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection. Dis Colon Rectum. 2005 Dec;48(12):2173-2179. doi: 10.1007/s10350-005-0179-5.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Patti R,
    2. Arcara M,
    3. Bonventre S,
    4. et al.
    Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids. Br J Surgery. 2008 Nov;95(11):1339-1343. doi: 10.1002/bjs.6236.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Maria G,
    2. Cassetta E,
    3. Gui D,
    4. Brisinda G,
    5. Bentivoglio AR,
    6. Albanese A
    . A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998 Jan 22;338(4):217-220. doi: 10.1056/NEJM199801223380402.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    1. Brisinda G,
    2. Maria G,
    3. Bentivoglio AR,
    4. Cassetta E,
    5. Gui D,
    6. Albanese A
    . A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999 Jul 8;341(2):65-69. doi: 10.1056/NEJM199907083410201.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Yiannakopoulou E
    . Botulinum toxin and anal fissure: efficacy and safety systematic review. Int J Colorectal Dis. 2012 Jan;27(1):1-9. doi: 10.1007/s00384-011-1286-5.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Valizadeh N,
    2. Jalaly NY,
    3. Hassanzadeh M,
    4. et al.
    Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial. Langenbecks Arch Surg. 2012 Oct;397(7):1093-1098. doi: 10.1007/s00423-012-0948-2.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Gandomkar H,
    2. Zeinoddini A,
    3. Heidari R,
    4. Amoli HA
    . Partial lateral internal sphincterotomy versus combined botulinum toxin A injection and topical diltiazem in the treatment of chronic anal fissure: a randomized clinical trial. Dis Colon Rectum. 2015 Feb;58(2):228-234. doi: 10.1097/DCR.0000000000000307.
    OpenUrlCrossRef
  63. 63.↵
    1. Goeschel H,
    2. Wohlfahrt K,
    3. Frevert J,
    4. Dengler R,
    5. Bigalke H
    . Botulinum A toxin: neutralizing and nonneutralizing antibodies – therapeutic consequences. Exp Neurol. 1997 Sep;147(1):96-102. doi: 10.1006/exnr.1997.6580.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Borodic G
    . Botulinum toxin, immunologic considerations with long-term, repeated use, with emphasis on cosmetic applications. Facial Plast Surg Clin North Am. 2007 Feb;15(1):11-16, v. doi: 10.1016/j.fsc.2006.10.001.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Slatkowski RM,
    2. Tyutyunikov A,
    3. Biglan AW,
    4. et al.
    Serum antibody production to botulinum A toxin. Ophthalmology. 1993 Dec;100(12):1861-1866. doi: 10.1016/s0161-6420(93)31384-9.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Dressler D
    . Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004 Mar;19 Suppl 8:S92-S100. doi: 10.1002/mds.20022.
    OpenUrlCrossRef
  67. 67.↵
    1. Mejia NI,
    2. Vuong KD,
    3. Jankovic J
    . Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005 May;20(5):592-597. doi: 10.1002/mds.20376.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords